Thursday, January 13, 2022
Imugene (IUGNF)
Three Innovative Platforms That Could Change Cancer Treatment
Imugene Ltd specializes in a clinical-stage immuno-oncology company. Its product includes HER-Vaxx,PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment being the Research and Development of oncolytic immunotherapies.
Robert LeBoyer, Senior Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Three Technology Platforms With Innovative Products. Imugene is developing novel immunotherapies that fight cancer by using oncoviruses, gene transfer, and antigen delivery. Its three technology platforms are in development to kill cancer cells directly, replace the use of monoclonal antibodies, or allow the use of CAR-T therapies in sold tumors.
Oncolytic Viruses Infect and Kill Cancer Cells. Imugene is developing two products that use modified viruses to target, infect, and kill cancer cells. The infected cells reproduce the virus, infect other cells, and stimulate an immune response. The first product, VAXinia, is in development for several types of metastatic advanced solid tumors. The second product, CHECKVaxx, also stimulates an …
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.